TOLEARN: 3 WAYS. LIVE meetings are produced. ONLINE products are produced by. PRINT materials are produced by. by Imedex in 15 countries

Transcription

1 April 30 May 1, 2010 I 4325 Alexander Drive Alpharetta, GA , USA 30 Imedex for your reference needs PRINT materials are produced by Imedex is committed to environmental excellence. This publication is printed on paper, which is acid-free and contains 30% post-consumer waste. 3 WAYS TOLEARN: ONLINE products are produced by Imedex in 6 user-friendly formats by Imedex in 15 countries LIVE meetings are produced

2 Organized for Organized for April 30 - May 1, 2010 Chairs Hagop M. Kantarjian, MD John P. Leonard, MD Weill Cornell Medical College Robert Z. Orlowski, MD, PhD 2 nd Announcement W W W. I M E D E X. C O M

3 April 30 May 1, 2010 I Letter from the Chairs Dear Colleagues, It is with great pleasure and enthusiasm that we invite you to attend Great Debates and Updates in Hematologic Malignancies, taking place April 30 May 1, 2010 in. Covering the broad continuum of hematologic malignancies, from lymphoma to leukemia to myeloma to myeloproliferative disorders, this one-of-a-kind hematology conference has a broad appeal to attendees and provides the most substantial curriculum. Using a combination of didactic presentations, as well as discussions in areas of controversy in hematology, the highly-informative debate format is one that you will find both enjoyable and educational. Attendees will have the chance to interact with nationally-recognized thought leaders who will take opposing positions on topics of interest and provide you with an insightful look at more than one side of a question. Discussions will focus on how the new data fits into the current community practice of hematology and will be aimed at facilitating rapid incorporation of important new advances in treatment into your current practice. For any healthcare professional interested and/or involved in the management and treatment of patients with hematologic malignancies, this conference is one that you will not want to miss! We look forward to seeing you in New York for what promises to be a rewarding professional update! Sincerely, Hagop M. Kantarjian, MD John P. Leonard, MD Robert Z. Orlowski, MD, PhD

4 April 30 May 1, 2010 I Continuing Medical Education Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for 12.5 of AMA PRA Category 1 Credit TM. Who Should Attend This educational activity is primarily targeted to academic and community hematologists and oncologists, and secondarily to oncology nurses and other health care professionals interested in the management of patients with hematologic malignancies. Corporate Support The following companies have provided an educational grant in support of this conference: Gold: Silver: Objectives After successful completion of this course, attendees should be able to: Identify the most effective therapeutic strategies and novel combinations for acute leukemias, especially for the care of elderly patients Correctly utilize imaging techniques to ensure successful management and validate response criteria for patients with non-hodgkin s lymphoma Review traditional treatment strategies for lymphoma and decide whether emerging, updated therapies could potentially optimize patient outcomes Determine how the emergence of novel agents in multiple myeloma could affect the use of markers for patient risk stratification and approaches to overcome treatment resistance Evaluate the optimal frontline approach to multiple myeloma treatment, including the most favorable number of agents, treatment sequencing, inclusion of novel agents, and the use of bisphosphonates for symptom management Determine how to effectively manage multiple myeloma patients with preexisting complications Conference Organizer Bronze: Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) , or by at cme@imedex.com Alexander Drive Alpharetta, Georgia , USA Tel.: +1 (770) Fax: +1(770) meetings@imedex.com

5 Faculty Asher A. Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, New York Morton Coleman, MD, FACP Center for Lymphoma and Myeloma Weill Medical College of Cornell University The New York-Presbyterian Hospitals Jorge E. Cortes, MD Harold P. Erba, MD, PhD University of Michigan Medical Center Ann Arbor, Michigan Eric J. Feldman, MD Weill-Cornell Medical College Rafael Fonseca, MD Mayo Clinic Scottsdale, Arizona Guillermao Garcia-Manero, MD Hagop M. Kantarjian, MD Shaji Kumar, MD Mayo Clinic Rochester, Minnesota John P. Leonard, MD Weill Cornell Medical College Sagar Lonial, MD Emory University Winship Cancer Institute Atlanta, Georgia Peter Martin, MD Weill Cornell Medical College Ruben A. Mesa, MD Mayo Clinic Rochester, Minnesota Craig Moskowitz, MD Memorial Sloan-Kettering Cancer Center Nikhil Munshi, MD Dana-Farber Cancer Institute Boston, Massachusetts Stephen Nimer, MD Memorial Sloan-Kettering Cancer Center Susan O Brien, MD Owen A. O Connor, MD, PhD New York University Langone Medical Center Robert Z. Orlowski, MD, PhD S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota Gail J. Roboz, MD Weill Cornell Medical College Gary Schiller, MD, FACP University of California Los Angeles Los Angeles, California Richard T. Silver, MD Weill Cornell Medical College Steven P. Treon, MD, PhD Dana-Farber Cancer Institute Boston, Massachusetts Andrew D. Zelenetz, MD, PhD Memorial Sloan-Kettering Cancer Center

6 Hotel Accommodations The Westin New York at Times Square 270 West 43rd Street Tel.: +1 (212) Fax: +1 (212) The fragrant aroma of White Tea welcomes you upon arrival at The Westin New York at Times Square. Discover 863 rooms and suites with a soothing color palette and views of New York City and the Hudson River. Utilize such modern amenities as high-speed internet access with wireless connectivity available in select rooms. Note the personal touches, like the custom-designed terry bathrobe. Experience a rejuvenated transformation when you awake in Westin s Heavenly Bed or step from Westin s Heavenly Bath. For the convenience of attendees, a limited number of rooms have been reserved until April 8, 2010 at a discounted rate of $229 single/double occupancy, plus tax, currently at 14.75%. This rate is not guaranteed outside the conference dates or after April 8, To reserve your room please contact the Westin New York at Times Square reservations department at (212) or visit the hotel s website at To receive the group rate, callers must identify themselves as being with the Great Debates and Updates in Hematologic Malignancies group. Reservation requests received after April 8, 2010 may not be guaranteed the group rate. Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/ or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT OF THIRD PARTIES RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED. In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual s own physician. Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society. Copyright 2010 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

7 Scientific Agenda Endorsed by Friday, April 30, :00 am Introduction 8:10 am Acute Leukemia Session Debate: Is chemotherapy still useful for APL in the era of ATRA and arsenic trioxide? ATRA + chemotherapy is still important Harold P. Erba, MD, PhD ATRA + non-chemotherapeutiic agents is better Gary Schiller, MD, FACP 8:35 am Debate: What is the most appropriate and effective therapy for elderly AML patients? High Intensity therapy Gary Schiller, MD, FACP Low Intensity therapy Harold P. Erba, MD, PhD 9:00 am Emerging novel and promising therapeutic agents for AML Stephen Nimer, MD 9:25 am Coffee Break 9:45 am Lymphoma Session I Debate: Should the results of interim PET scans change the planned management of advanced Hodgkins Lymphoma or Diffuse Large B-cell Lymphoma? Yes Morton Coleman, MD No Craig Moskowitz, MD 10:10 am Debate: Should surveillance CT scans be performed on DLBC Lymphoma patients who achieve a CR from frontline therapy? Yes Andrew D. Zelenetz, MD, PhD No Peter Martin, MD 10:35 am Debate: What is the most appropriate second line therapy for advanced Follicular Lymphoma patients who relapse following frontline R-CHOP? Autologous Stem Cell Transplant Craig Moskowitz, MD Radioimmunotherapy Andrew D. Zelenetz, MD, PhD Systemic chemotherapy John P. Leonard, MD 11:05 am What is the most appropriate management for stage I Follicular Lymphoma in a young patient deciding when and with what to initiate therapy? John P. Leonard, MD 11:35 am Lunch 12:40 pm Myeloma Session I Debate: Since novel agents appear to abrogate the negative impact of poor risk cytogenetics, are cytogenetics by FISH still a necessary part of risk stratification for newly diagnosed Multiple Myeloma patients? Yes Sagar Lonial, MD No S. Vincent Rajkumar, MD 1:05 pm Debate: What is the most appropriate frontline regimen for transplant ineligible Myeloma patients? MPT Steve P. Treon, MD, PhD MPV Sagar Lonial, MD MPR S. Vincent Rajkumar, MD 1:30 pm Debate: How should bisphosphonates be utilized in Multiple Myeloma patients responding to frontline therapy? 2 years of bisphosphonates therapy is appropriate for most patients Nikhi Munshi, MD Briefer courses are more appropriate for most patients Robert Z. Orlowski, MD, PhD 1:55 pm Debate: For newly diagnosed SCTeligible Myeloma patients the most appropriate induction therapy is: A two drug regimen Sagar Lonial, MD A three drug regimen Nikhi Munshi, MD A four drug regimen Shaji Kumar, MD 2:35 pm Coffee Break

8 *Please visit for the most up-to-date agenda and to register Friday, April 30, :55 pm CML Session Debate: What is the best tyrosine kinase inhibitor for frontline therapy of CML? Imatinib is still the standard of care Eric J. Feldman, MD New generation TKIs are the new standard of care Hagop M. Kantarjian, MD 3:25 pm Debate: What is the most appropriate salvage therapy for post-imatinib failure in CML? Allogeneic SCT Stephen Nimer, MD Second generation TKIs Jorge E. Cortes, MD 3:55 pm Evolving & promising therapeutic strategies for post-tki failure in CML Hagop M. Kantarjian, MD 4:20 pm Adjourn Saturday, May 1, :05 am CLL Session Moderator: James Epstein, MD Debate: FCR is the best frontline therapy for CLL patient 65 years of age Yes, FCR is the new standard of care Susan O Brien, MD No, chlorambucil based therapy is the standard of care Asher A. Chanan-Khan, MD 8:30 am Debate: How prominent should the roles of lenalidomide, bendamustine and ofatumumab be in the frontline therapy of CLL? No significant role Susan O Brien, MD Major significant role Asher A. Chanan-Khan, MD 8:55 am Myeloproliferative Neoplasm Session Moderator: Richard T. Silver, MD How I deal with the difficult questions in the Management of Essential Thrombocythemia Ruben A. Mesa, MD 9:25 am What is the role of allogeneic transplantation in Myeloproliferative Neoplasms? Allo-SCT should be used earlier and more often in MPNs Ronald Hoffman, MD Allo-SCT should be used only when systemic therapy is inappropriate or has failed Ruben A. Mesa, MD 9:50 am Coffee Break 10:10 am Myeloma Session II How I manage Multiple Myeloma patients who present with significant pre-existing illnesses or serious complications of the Myeloma: A 51 year old man presents with light chain Myeloma and a serum creatinine of 5.5 mg/dl Rafael Fonseca, MD A 46 year old woman with juvenile diabetes presents with IgG-lambda Myeloma and evidence of significant peripheral neuropathy Shaji Kumar, MD A 68 year old former professional wrestler with a long history of back and joint problems is diagnosed with IgG-kappa Myeloma and multiple vertebral compression fractures S. Vincent Rajkumar, MD

9 Scientific Agenda continued Endorsed by Saturday, May 1, :50 am Debate: For newly diagnosed Multiple Myeloma patients who relapse from a VGPR response more than 12 months following frontline therapy, what is the best salvage strategy? Re-treat with the previously effective frontline therapy Robert Z. Orlowski, MD Alternate immunomodulatory based regimens with proteasome inhibitor based regimens Rafael Fonseca, MD 11:15 am The next great therapeutic challenge in Multiple Myeloma: Designing novel agents and combinations to overcome myeloma cell resistance to proteasome and immunomodulatory agents Nikhi Munshi, MD 11:40 am Debate: Do nucleoside analogues still have a role in the frontline therapy of symptomatic Waldenstroms Macroglobulinemia? 12:10 pm Lunch Yes Shaji Kumar, MD No Steven P. Treon, MD, PhD 1:10 pm Lymphoma Session II Moderator: James Epstein, MD Emerging and Promising Novel Agents for B-cell and T-cell Lymphomas Owen A. O Connor, MD, PhD 1:40 pm Debate: Should treatment for limited stage non-bulky Hodgkins Lymphoma include radiation therapy? Yes Peter Martin, MD No Morton Coleman, MD 2:05 pm Coffee Break 2:25 pm MDS Session Moderator: Richard T. Silver, MD Debate: What is the best therapy for MDS patients with deletion 5q? Lenalidomide is the best choice for all deletion 5q patients Gail J. Roboz, MD Lenalidomide is not the best choice for most deletion 5q patients Guillermao Garcia-Manero, MD 2:50 pm Debate: What is the best frontline therapy for intermediate-2 and high risk MDS? Azacytidine is the standard of care Gail J. Roboz, MD The standard of care is not yet well defined Eric Feldman, MD 3:15 pm Novel & Evolving Therapeutic Strategies for MDS Guillermo Garcia-Manero, MD 3:40 pm Summary 3:50 pm Adjourn

10 April 30 May 1, 2010 I AUDIENCE PARTICIPATION A Hands-On Experience During the scientific sessions, speakers and the audience can exchange information through a hands-on computerized speaker-audience interaction system. With this state-of-the-art equipment, participants answer multiple choice questions, and within seconds, the answers are calculated and projected on a screen in tabular or graphic form for all to see. This system maximizes the ability for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other. Important Dates Regular Registration Deadline April 22, 2010 Presentation Dates April 30 May 1, 2010 Quotes Very good conference continue with similar format in the future Excellent clinical meeting Excellent conference good speakers Great, well-organized conference!

11 April 30 May 1, 2010 I CONFERENCE REGISTRATION A FIRST NAME LAST NAME DEGREE: qmd qphd qpharmd q RN q Other SPECIALTY: q Hematology q Medical Oncology q Radiation Oncology q Pathology qsurgery qnursing qother ADDRESS TELEPHONE FAX INSTITUTE DEPARTMENT ADDRESS CITY STATE / PROVINCE ZIP / POSTAL CODE COUNTRY q Check if you require special facilities or assistance and attach a note with specific details and requirements. REGISTRATION FEES q Regular...$ If payment received by April 22, 2010 q Full/Onsite...$ If payment received by April 22, 2010 q Nurses/Residents/Students*...$75.00 *proof of eligibility must accompany registration PAYMENT METHOD Credit card transactions will appear under the name Imedex, Inc. on your next statement. qamerican Express qmastercard qvisa qcheck in the amount of $ Card No. Exp. Date: / Cardholder s Name: Signature: NOTE: After April 22, 2010 only credit card payments will be accepted for pre-registration. To pre-register, registration and payment must be received no later April 22, Please register onsite after this date. Contact Imedex at +1 (678) or visit our website at to ensure that the meeting is being held as scheduled and to confirm that the meeting is not full. For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 22, The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 22, Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda content is subject to change without notice.

12 Registration Fees Regular...$ If payment received by April 22, 2010 Full/Onsite...$ If payment received by April 22, 2010 Nurses/Residents/Students*...$75.00 *proof of eligibility must accompany registration Registration Procedures To Register: You may register online by April 22, 2010 at by calling Imedex at +1 (678) or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified. Payment: To pre-register, registration and payment must be received no later than April 22, Please register onsite after this date. Contact Imedex at +1 (678) or visit our website at to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received. Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda. Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 22, The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 22, The Registration and Information Desk will be staffed: Friday, April 30, :00 am 5:00 pm Saturday, May 1, :00 am 4:30 pm 4 EASY WAYS TO REGISTER: ONLINE... FAX US... You can fax your registration 24 hours a day. +1 (678) CALL US... The Registrar will take your registration over the phone. +1 (678) MAIL US... Imedex 4325 Alexander Drive Alpharetta, GA , USA Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.